INDO US BIO-TECH Q2 FY27 (STANDALONE) ; NET LOSS AT ₹4 CR VS PROFIT ₹3 CR (YOY), PROFIT ₹3 CR (QOQ)

REVENUE DOWN 51% AT ₹15 CR (YOY), DOWN 53% (QOQ) EBITDA LOSS ₹3 CR VS PROFIT ₹4 CR (YOY), PROFIT ₹3 CR (QOQ) MARGINS AT -16.90% VS 13.90% (YOY), 9.70% (QOQ)

INDO TECH TRANSFORM LTD.

← Back to feed